Clinical Trials Browser

Recruiting × INDUSTRY × Ipilimumab × Clear all

Carcinoma, Non-Small-Cell Lung

NCT07291076 2026-04-14

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Phase 1/2 Recruiting

129 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Phase 1/2 Recruiting

126 enrolled

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT06743126 2026-04-13

SUPRAME

Phase 3 Recruiting

360 enrolled

Dermatologic

Melanoma, Cutaneous Malignant

NCT07227012 2026-04-08

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Phase 1/2 Recruiting

138 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05533697 2026-04-03

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT04665206 2026-04-02

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Phase 1/2 Recruiting

434 enrolled

Other solid neoplasmThoracic

Mesothelioma

NCT06097728 2026-04-02

eVOLVE-Meso

Phase 3 Recruiting

825 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT06581406 2026-04-02

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Phase 2/3 Recruiting

280 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

1,500 enrolled

Tumor-Agnostic

Neoplasms

NCT07293351 2026-03-31

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Phase 1/2 Recruiting

234 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05536141 2026-03-30

ARC-20

Phase 1 Recruiting

362 enrolled

Genitourinary

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT07176650 2026-03-16

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Phase 1 Recruiting

246 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05176483 2026-03-12

STELLAR-002

Phase 1 Recruiting

1,314 enrolled

GastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

134 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT05584670 2026-01-20

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

542 enrolled

Other solid neoplasm

Solid Tumor

NCT06624644 2025-09-10

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Phase 2/3 Recruiting

135 enrolled

Dermatologic

Melanoma

NCT03645928 2025-06-19

LN-144

Phase 2 Recruiting

245 enrolled

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06514651 2024-07-23

MAQ-001 in Patients With Advanced Solid Tumors

Phase 1 Recruiting

30 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06399419 2024-05-30

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Phase 1 Recruiting

28 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04291755 2024-04-05

Development and Analysis of a Stool Bank for Cancer Patients

Recruiting

100 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Clinical Trials

CheckMate-1533

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

SUPRAME

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

eVOLVE-Meso

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Pan Tumor Rollover Study

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

ARC-20

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

STELLAR-002

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

LN-144

MAQ-001 in Patients With Advanced Solid Tumors

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Development and Analysis of a Stool Bank for Cancer Patients